Peer-influenced content. Sources you trust. No registration required. This is HCN.

JAMA NetworkUptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy

In this cohort study of 34,131 patients with cancer published in JAMA Oncology, trial ineligibility was associated with a greater likelihood of immune checkpoint inhibitor (ICI) monotherapy use compared with non-ICI therapy. Among trial-ineligible patients, there were no overall survival differences between treatment with ICI monotherapy, ICI combination therapy, and non-ICI therapy.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form